IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: A comparative case series

Eur J Haematol. 2017 Apr;98(4):378-387. doi: 10.1111/ejh.12842. Epub 2017 Jan 20.

Abstract

Objective: To compare the clinical and laboratory features of IgG4-related disease (IgG4-RD) and lymphocyte-variant hypereosinophilic syndrome (L-HES), two rare diseases that often present with lymphadenopathy, gastrointestinal symptoms, eosinophilia, and elevated immunoglobulins/IgE.

Method: Comparative case series of 31 patients with IgG4-RD and 13 patients with L-HES.

Results: Peripheral blood eosinophilia was present in eight of 31 patients with IgG4-RD compared to 13 of 13 patients with L-HES (median eosinophils 0.4 vs 7.0 giga/L, P=.001) and 12 of 20 patients with IgG4-RD had increased serum IgE compared to eight of 13 patients with L-HES, P=.930. Twenty-seven of 30 patients with IgG4-RD had elevated serum IgG4 compared to five of 12 patients with L-HES (median IgG4 9.6 g/L vs 0.80 g/L, P=.002). Flow cytometry demonstrated an aberrant T-cell phenotype in 7 of 23 patients with IgG4-RD and 13 of 13 patients with L-HES (P<.001). T-cell clonality by PCR was positive in 12 of 23 patients with IgG4-RD vs 10 of 13 patients with L-HES (P=.143). Patients in both groups received corticosteroids as first-line therapy. For refractory disease in IgG4-RD, rituximab was the most common steroid-sparing agent, whereas in L-HES, it was pegylated interferon-α-2a.

Conclusion: The overlapping features of these two diseases with divergent treatment options demonstrate the importance of familiarity with both entities to optimize diagnosis and treatment.

Keywords: IgG4; IgG4-related disease; eosinophil; hypereosinophilic syndrome; hypergammaglobulinemia.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage*
  • Adult
  • Aged
  • Female
  • Humans
  • Hypereosinophilic Syndrome* / blood
  • Hypereosinophilic Syndrome* / diagnosis
  • Hypereosinophilic Syndrome* / drug therapy
  • Immunoglobulin G / blood*
  • Interferon-alpha / administration & dosage*
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage*
  • Recombinant Proteins / administration & dosage
  • Rituximab / administration & dosage*
  • T-Lymphocytes*

Substances

  • Adrenal Cortex Hormones
  • Immunoglobulin G
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Rituximab
  • peginterferon alfa-2a